Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .

Inclusion Criteria: * Metastatic colorectal cancer with histological proof * Measurable disease according RECIST 1.1 * Age ≥ 70 years * ECOG ≤ 1 * Biological values Haemoglobin ≥ 9 g/dL, PNN ≥ 1500/mm3, platelets≥ 100 000/mm3, bilirubin ≤ 1,5N, ASAT, ALAT et PAL ≤ 2,5N (≤ 5N if hepatic metastases), lipase ≤1,5N, TP≥ 70%, Creatinine clairance ≥ 30 mL/min * Patient without response to 5FU chemotherapy or anti-vegf treatment or anti EGFR treatment (if RAS wild-type), in progression during this treatment or treatment stopped because of toxicities * Geriatric Questionnaires answered * Life-expectancy ≥ 3 months * Informed Consent Signed Exclusion Criteria: * Not able to swallow tablets (crushed tablets are not allowed) * Previous treatment with regorafenib or other multikinase treatment * Other cancer during the last 5 years, excepted in-situ cervix cancer, skin cancer non melanoma and cancer of the bladder curatively treated * Radiotherapy: with extended fields in the last 4 weeks, with limited fields in the last 2 weeks previous inclusion * Toxicity \> grade 1 not resolved with previous treatment * Major surgery in the 28 days before the inclusion * Non cicatrized injury, ulcer or bone fracture * Congestive Cardiac insufficiency classe \>2 (NYHA) * Unstable angor in the last 3 months * Myocardial Infraction in the 6 months before inclusion * HTA not controlled * Pheochromocytome * Arterial or venous thromboembolism in the past 6 months * Infection of grade \> 2 * VIH infection * B or C hepatitis necessiting a specific treatment * Cirrhosis * Suspicion of brain metastasis or brain metastasis * Haemorraghe ofgrade \>3 in the last weeks * Symptomatic Pulmonary fibrosis * Proteinuria \> grade 3 * Malabsorption * Allergy know to the treatment or to one similar treatment or to one treatment component * Systemic anti-cancer drug during the study or the the last 4 weeks * Concomitant treatment with CYP3A4 inhibitor or inductor or with UGT1A9 inhibitor * Social, psychological or medical condition which can interfere with the study participation